Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Idogen's work on capitalization has not yet achieved the required result. Idogen is now evaluating, among other things, the possibility of a reverse acquisition. If capital is not added to the company, the board will propose a liquidation.
"Idogen announced in a press release on April 3 that the funds will last until the end of June. The work on this year's capitalization has not yet obtained the required result. Idogen is now investigating, among other things, the possibilities for a reverse acquisition (i.e. another company takes over Idogen's listing at the stock market through a number of transactions. Idogen has around 4,000 shareholders). Idogen has tax carry forward losses of approximately 260 million SEK. If results are not reached from these discussions, Idogen will work for a liquidation. This will be decided at the annual general meeting on June 9 at the latest.
Idogen continues to work on drawing up a control balance sheet.
"We work with several financing options. However, time is short and therefore we are evaluating a reverse acquisition in parallel. If we do not reach the goal with our various capitalization processes, we must liquidate the company before the cash and equity run out. As we should in these situations, we are in dialogue with both our Certified Adviser and Nasdaq." says Christina Herder, acting CEO.
For further information, please contact:
Christina Herder, acting CEO, Idogen AB
Tel: +46 70374 71 56
E-mail: christina.herder@idogen.com
The information was submitted for publication through the agency of the contact persons set out above on April 18, 2023, at 08:01 CET.
Certified Adviser:
Vator Securities AB
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced program, IDO 8 - now in clinical phase - is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies.For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company's technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T) and autoimmune diseases (IDO AID).More information about Idogen is available via www.idogen.com.